Results 141 to 150 of about 119,956 (261)
Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song +7 more
wiley +1 more source
IL‐1β upregulates the protein level of WTAP, which promotes the m6A modification of ACSL4 mRNA in an IGF2BP2‐dependent manner, thereby enhancing its stability. The increased ACSL4 drives lipid peroxidation, leading to lysosomal membrane permeabilization (LMP) and impaired mitophagy, which collectively accelerate intervertebral disc degeneration (IVDD).
Shu Jia +8 more
wiley +1 more source
A concept of integrated O2 and H2 gas therapy is achieved using a gas‐producing material. PMP nanoparticles, fabricated from platinum, MIL‐101(Fe)‐NH2, and phosphotungstic acid, are integrated into bilayer gelatin methacryloyl microneedles for transdermal delivery. These microneedles enable integrated O2 and H2 gas therapy and promote wound healing via
Zesheng Chen +13 more
wiley +1 more source
An m6A‐modified circRNA, circPSMB1, is identified as a tumor suppressor in chordoma. METTL3‐dependent m6A promotes circPSMB1 interaction with HNRNPA2B1, limiting c‐MYC expression and malignant progression. An injectable HMnO2‐based nanohydrogel enables local circPSMB1 delivery and tumor microenvironment‐responsive therapy, offering a promising strategy
Yingchuang Tang +7 more
wiley +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai +12 more
wiley +1 more source
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li +9 more
wiley +1 more source
This study identifies ALYREF as an oncogenic m5C reader in endometrial cancer. ALYREF recognizes NSUN2‐mediated m5C modification on XRCC6 mRNA to enhance transcript stability and increase XRCC6 expression. Elevated XRCC6 activates Wnt/β‐catenin signaling, resulting in accelerated tumor cell proliferation, migration, invasion, and xenograft tumor growth.
Linlin Hao +8 more
wiley +1 more source

